control iq data reson doctor bump
estim pt launch
host meet manag includ john sheridan
presid ceo leigh vossel evp cfo blickenstaff execut
chairman much discuss center around releas control iq
data ada meet think data posit stock
reaction especi peel back layer data set see enthusiasm shown
doctor meet compani reiter launch control iq
believ lead increas penetr adopt agre
rais pt base new forecast
prior pt base
result better headlin interpret
view differ time rang number
refer pilot studi report studi wall
street issu clinic one notabl standard time rang
clinician patient make decis like view time rang
time loop posit algo issu also penal result
estim note popul studi less well control
prior one see room improv system futur look
tweak algorithm net-net expect patient commun excit
control iq note patient studi vote stay therapi
grow pie gain share
believ acceler pump market look data
disclosur competitor view signific shift begin
peopl come renew year half new pump
user come mdi half competit convers roughli
equival market share three piec grow roughli concert
valuat pt prior base prior rev
trade revenue peak pt assum
multipl come slightli growth moder tough comp
trade data key metric
compani account thomson reuter ub estim ub adjust ep state goodwill-rel charg adjust abnorm econom item analyst
judgement valuat base averag share price year base share price jun edt
report prepar ub secur llc except core rate band page analyst certif
requir disclosur begin page ub seek busi compani cover research
report result investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
control iq result impress clinician excit patient
believ data help propel commerci result increas
penetr rate reiter launch control iq us late year
journal public like late summer pediatr launch like
ou launch countri countri start next year still unclear
whether control iq free upgrad garner addit reimburs
take data payer
look one level data know mix patient
go studi wide rang peopl diabet
conclus comprehens studi ever
run awar type patient would includ
studi nih fund previous experi pilot
trial time loop note initi issu
algorithm remedi trial work result
may decreas time rang well time loop
lower level time rang overal differ
treatment control arm signific delta compar well
studi natur addit dawn effect show period
night time rang went high import sell point
patient parent worri overnight low also present data
ped french studi includ time rang kid night
believ typezero one best algorithm today
licens test algorithm hundr
studi sever hundr hour clinic data part perform
driven aggress tack night prove right decis
patient move eat algorithm aggress one
issu typezero algorithm perform hyperglycemia
algorithm aggress lower end target lower number could
allow time rang
beyond number glucos control tell see satisfact score
high level patient enthusiasm pump perhap tell
score patient want continu use pump score
safeti profil pump also robust side effect
next gen algorithm simplifi user interfac still
see element current user interfac improv stage
think cgm limit factor system view
perform good highlight reduc size could
improv on-bodi perform provid addit benefit
compar control iq data basal iq data note basal iq
data compar good peopl studi well
control despit see substanti gravit toward devic
real life
sport smaller on-bodi profil
sport reiter timelin sport launch late
ace pump pathway full phone control includ
bolu phone form factor smaller day cartridg
attach bodi adhes patch pump
form factor believ allow compet
effect given approv yet market number
manuscript expect publish next year allow doctor
see data
capac set volum upgrad opportun anima
current manufactur capac produc pump
annual line produc cartridg year could
support user year continu order suppli given cartridg
line take longer get run begun invest three new
line capac doubl total capac
upgrad program success help folk
warranti upgrad also advertis rebat anima
offer patient remind began prioriti access program
spring folk could come warranti come
year expect renew next month
month prior could benefit
difficult compar data data complianc
rate lower control arm compar baselin
data peopl studi gener well control
announc tidepool interest could gener posit
buzz/market view size tidepool/th do-it-yourself commun larg
enough make big swing market product probabl year
regard libr would assum abl garner icgm
design fda ensur sensor lead neg effect
harm peopl order work libr compani would need form
busi partnership understand integr devic
pump get better understand inform sent near
field commun bluetooth frequent could occur
multipl examin fundament analysi show valuat
recent
trade con sale averag
within rang price target
sale assum multipl moder slightli tougher comp
slow growth execut on-going launch basal-iq launch
control-iq share de-rat sinc begin
despit strong beat period re-rat
earli august due enthusiasm basal iq pump integr
cgm us approv june gain share
half new pump come mdi patient balanc anima
competitor think compani remain track bring control-iq
market us submit sport approv expect
year end
average rel
ev/sal rel
trade premium
trade turn closest comp term size due
fact diabet pure play view trade
premium due faster revenu growth think spread
narrow maintain growth growth normal
upsid downsid
upsid upsid case assum achiev sale growth
next two year also factor ebit margin pump
market growth
base base case assum achiev sale growth
next two year also factor ebit margin pump market
growth mid-teen
downsid downsid case assum achiev sale
growth per year next two year also factor ebit margin
pump market growth
profit tax
profit tax
equival
invest asset
trade payabl st liabil
net incom pref div
net chang work capit
chang debt pref share
flow inc/ dec cash
balanc sheet inc/ dec cash
compani account ub estim ub metric use report figur adjust ub ep ub dilut calcul use ub net incom ad back depreci
buy minor
revenu divis us
ebit ub divis us
compani account ub estim ub metric use report figur adjust ub analyst
valuat method risk statement
price target base revenu estim mm
risk price target includ slowdown insulin pump market
competit other price reimburs risk
regulatori risk around pipelin lack insur coverag margin
pressur cost inflat busi execut problem
